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A novel “Powder Solution Technology” involves absorption and adsorption efficiency which makes use of 
liquid medications, drug suspensions admixed with suitable carriers, coating materials and formulated into 
free flowing, dry looking, non adherent and compressible powder forms. Based upon a new mathematical 
model expression, improved flow characteristics and hardness of the formulation has been achieved by 
changing the proportion of Avicel ® PH 200 and Aerosil ® PH 200 from 50:1 ratio to 5:1 and in which the 
drug is dispersed in an almost molecularly state. Due to their significantly improved wetting properties 
a greater drug surface area is exposed to the dissolution media, resulting in an increased dissolution rate 
and bio availability. By using the Liquisolid technique, sustained drug delivery systems were developed 
for the water soluble drugs in which hydrophobic non-volatile solvents are used as vehicles.
Uniterms: Liquisolid. Solubility. Bioavailability. Flow properties. Load factor. Powder solution 
technology.
A nova “Tecnologia da Solução Sólida” envolve eficiência de absorção e de adsorção, faz uso de 
medicações líquidas, suspensões de fármacos e misturas com transportadores adequados, materiais 
de cobertura e é formulada em formas sólidas em fluxo livre, secas, não aderentes e compressíveis.  
Com base em novo modelo matemático, características aprimoradas de fluxo e dureza da formulação 
foram alcançadas modificando-se a proporção de Avicel ® PH 200 e Aerosil ® PH 200 de 50:1 para 5:1, 
na qual o fármaco é disperso quase que no estado molecular. Devido às propriedades de umidificação 
significativamente aprimoradas e à área do fármaco exposta ao meio de dissolução, que resulta na 
velocidade de dissolução, a biodisponibilidade foi aumentada. Utilizando a técnica Liquisólido, 
desenvolveram-se sistemas de liberação controlada de fármacos solúveis em água, nos quais solventes 
hidrofóbicos não voláteis foram usados como veículos. 
Unitermos: Liquisólido. Solubilidade. Biodisponibilidade. Propriedades de fluxo. Fator de carga. 
Tecnologia de solução sólida. 
INTRODUCTION
The poor dissolution characteristics of water in-
soluble drugs are a major challenge for pharmaceutical 
science. Powder solutions are designed to contain liquid 
medications in powdered form and there have been nume-
rous advances in increasing drug dissolution rate profiles. 
During the past few years many techniques have been de-
veloped such as drug micronization, solid dispersions, co- 
precipitation, lyophilization, micro– encapsulation, use of 
pro-drug and drug derivatization processes, and inclusion 
of drug solutions into soft gelatin capsules (Kapsi, 2001).
Micronization is the most common method used 
to increase the surface area of the drug, but this becomes 
less effective when they are formulated as tablets or 
encapsulations (Aguiar et al., 1979; Finholt, 1968; Lin 
et al., 1968). In the case of soft gelatin capsules, Ebert’s 
(1977) review stated that these products demonstrated the 
most efficient bio availability since the drug is already in 
solution form. However, the formulation of soft gelatin 
capsules is expensive and requires sophisticated technol-
ogy. Nevertheless, best approaches are available to prepare 
the liquid oily medications and drug solutions of water 
insoluble solid drugs.
Bio-Pharmaceutical classification class II (water 
insoluble drugs), the rate of oral absorption is often con-
trolled by the rate in the GIT. Therefore, together with 
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permeation, solubility profile and dissolution rate profiles 
of drugs are major key factors for its oral bio-availability. 
The concept of powdered solutions makes it possible to 
convert drug solutions or liquid medications into mode-
rately flowing powders by an admixture with selected 
powder excipient. Some investigators have used a similar 
approach to increase release profiles of several water–in-
soluble drugs (Spireas, 2002).
A latest contemporary technique, authorized “Po-
wder Solution Technology” has been implemented to 
prepare water-insoluble drugs into prompt release solid 
dosage forms. The Liquisolid techniques are considered 
as pleasantly flowing and compressible powdered forms 
of liquid medications. These liquid medications may 
be regenerated into dry – looking or moistureless, non- 
adherent free-flowing and readily compressible powders 
by a simple admixture with selected carriers and coating 
materials. In this technique, the drug might be in solid 
dosage form and dissolved in solution or a solvent. Drug 
is solubilized in a maximum molecularly dispersed state. 
Therefore, this is due to their significantly increased wet-
ting properties and increased surface area of drug available 
for dissolution. Water– insoluble or poorly water soluble 
drugs may be expected to have increased dissolution rate 
properties as well as improved bioavailability.
The Liquisolid compacts have two major formu-
lation components namely, powder substrate and liquid 
medication. The powder substrate mainly consists of: a) 
compression enhancing, large preferably porous carrier 
particles; b) flow enhancing, very fine, highly adsorptive 
coating material particles. Liquisolid preparations may be 
hampered by their poor and erratic flow and compaction 
properties. Inherently, the acceptable flow and compaction 
characteristics of the finished powder / liquid admixtures 
are secured. 
The quantities of various excipients required for po-
wder solution formulations are determined in accordance 
with a new mathematical model expression (Liao, 1983). 
The absorbate molecules diffuse inside the absorbent and 
are eventually captured by the powder particles within their 
bulk, and thus absorption of the liquid occurs. Adsorption 
is the phenomenon in which liquid is not truly absorbed 
and instead of being dispersed through out the interior of 
the solid, the molecules only cling to its available surface, 
internal and external. However, depending on the sorbent 
properties, both of these processes can occur simultaneous-
ly, and is termed sorption. Initially the liquid is absorbed in 
the interior of the particles captured by its internal structure 
and after saturation of this process adsorption of the liquid 
onto the internal and external surfaces of the porous carrier 
particles occurs (Rania et al., 2008).
DEFINITIONS
Liquid medication: liquid lipophilic drugs and drug 
suspensions or solutions of solid water – insoluble drugs 
in suitable non volatile solvent systems are called Liquid 
medication.
Solubility: water insoluble drugs include those dru-
gs that are “sparingly water soluble” (one part solute into 
30-100 parts of water), slightly water- insoluble (one part 
solute into 1000 -10,000 parts of water) and practically 
“water-insoluble” or insoluble (one part solute into 10,000 
or more parts of water). 
The liquisolid technique systems refers to powdered 
forms of liquid medications formulated by changing to 
liquid lipophilic drugs or drug suspensions or solutions of 
water insoluble solid drugs in suitable non-volatile solvent 
systems into dry-looking, non-adherent, free moderately 
flowing.
Liquisolid systems based on the type of liquid me-
dication can be classified into three sub groups: 
(i)“Powdered drug solutions”
(ii)“Powdered drug suspensions”
(iii)“Powdered liquid drug ”
The first two groups may exist or be produced by 
changing drug solutions and drug suspensions while the 
third is produced from the formulation of liquid drugs into 
liquisolid systems.
“Liquisolid compacts”: refers to immediate sus-
tained-release tablets or capsules that are described under 
“liquisolid systems”.
“Liquisolid Microsystems”: refers to capsules 
prepared by “liquisolid systems” plus  the inclusion of an 
additive resulting in a unit size that may be as much as five 
times less than that of a liquisolid compact.
Liquid load factor (Lf): defined as the ratio of the 
amount of liquid medication (W) over the quantity of 
carrier material (Q) in the system.
 
WLf = ––
 Q
Carrier: Coating Material Ratio (R): Ratio be-
tween the quantities of carrier (Q) and coating materials 
(q) present in the formulation. 
    
QR = ––
 
q
“Carrier material”: refers to a preferably porous 
material possessing sufficient absorption properties.
“Coating Material”: refers to a material possessing 
fine and highly adsorptive particles.
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ADVANTAGES
1) Large number of Bio – Pharmaceutical classi-
fication class 2 drugs with high permeability, slightly 
or very slightly water soluble and practically insoluble 
liquids and solid drugs can be formulated into Liqui-
solid systems.
2) Improvement of Bio-availability of an orally 
administered water insoluble drugs is achieved 
3) This principle governs or administers the mecha-
nism of drug delivery from liquisolid systems of powdered 
drug solutions and it is mainly responsible for the impro-
ved dissolution profiles exhibited by this preparations.
4) Drug is formulated in a tablet form or encapsu-
lated dosage form and is held in solubilized liquid state, 
which confers developed or improved drug wetting pro-
perties thereby improving drug dissolution profiles.
5) In this technique, production cost is low compared 
to soft gelatin capsules.
6) This liquisolid system is specifically for powdered 
liquid medications.
7) Greater drug surface area is exposed to the dis-
solution medium.
8) These Liquisolid systems formulate into imme-
diate release or sustained release dosage forms.
9) Optimized sustained release Liquisolid tablets or 
capsules of water insoluble drugs demonstrate constant 
dissolution rates (Zero Order Release).
DISADVANTAGES
1) This technique is only for water insoluble drugs.
2) However, for formulation of high dose insoluble 
drugs the liquisolid tablet is one of the limitations of this 
technique.
3) In order to achieve acceptable flow ability and 
compactability for liquisolid powder formulation, high 
levels of carrier material and coating materials should be 
added. This will increase the weight of tablets to above one 
gram which makes them difficult to swallow. Therefore, it 
is impossible with conventional tablet methods to convert 
high dose to liquisolid tablets with a tablet weight of less 
than50 mg. Dissolution profile enhancement occurs in 
the presence of low levels of hydrophilic carrier, where 
coating material is not significant. 
FORMULATION DESIGN
Non-Volatile solvents: Poly Ethylene Glycol 
(PEG)-400. PEG- 200, PEG- 4000, PEG- 6000, Polysor-
bate80, Tween–80, Propylene Glycol (PG) etc.
Carriers: Avicel® RTM 105, Avicel® PH 102 granu-
lar Microcrystalline cellulose (MCC) grade, Avicel ® PH 
200 coarse granular MCC grade, experimental grade of 
granular amorphous cellulose (E.G.C) starch, lactose used 
as carrier materials. Silica possessing large surface areas 
and MCC of fine particle size granular grades produced 
good flow properties and compression properties resulting 
in applicable tablets. 
Super Disintegrates: Sodium starch glycolate 
(SSG), Crospovidone, Sodium croscarmellose .
Coating Materials: Aerosil® PH 200, Colloidal 
silica, Cab-O-sil RTM M5 used as coating material. By 
adding PVP to liquid medication, it would be possible to 
produce dry powder formulations containing liquid with 
a high concentration of drug.
The active pharmaceutical ingredient in a solid 
dosage form must undergo dissolution before it is avai-
lable for absorption from the gastro intestinal tract. The 
dissolution rate is most often the rate-determining step in 
passive drug absorption. Liquisolid system demonstrated 
for drugs which would enhance the dissolution profile 
and the absorption capacity of water insoluble solid drugs 
such as digoxin, digitoxin, prednisolone, hydrocortisone, 
famotidine, carbamazepine, water insoluble vitamins, 
hydrochlorothiazide, Domperadone, spiranolactone, Car-
vedilol, Naproxen, and Meloxicam .
GENERAL PROCEDURE FOR LIQUISOLID 
TABLETS
The Liquisolid tablet preparation method involves, 
first a mathematically calculated amount of pure drug 
weighed and dissolved in the suitable amount of solvent 
in a molecularly dispersed state. For attaining good flow 
properties trial and error methods were used i.e. chan-
ging the carrier : coating material ratio from 50:1 to 5:1 
ratios according to  new mathematical model expressions 
proposed by Liao. This liquid medication is poured on 
the suitable amount of carrier material. The liquid medi-
cation is absorbed into the carrier material internally and 
externally and then a suitable disintegrant was added to 
this material. Finally, coating material was added for dry 
looking, adherent to the carrier material for achieving good 
compression properties. Liquid medication is incorporated 
into carrier material which has a porous surface and closely 
matted fibers in its interior as cellulose. Both absorption 
and adsorption take place, i.e. first, the liquid absorbed 
into the interior of the particles is captured by its internal 
structure, and after saturation of this process, adsorption 
of the liquid onto the internal and external surface of the 
porous carrier particles occurs. A large surface area and 
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high absorptive properties of the coating material gives the 
Liquisolid system the particular flow properties described 
(Martin et al., 1983; Spireas et al., 1992).
Solubility Studies: Solubility studies were con-
ducted for the selection of high solubility of the pure 
drug form in the non volatile solvents, This involves pure 
drug dissolved in different non-volatile solvents. Excess 
amounts of pure drug were added to the non-volatile sol-
vents, followed by saturation solution transfer to a rotatory 
shaker for 48 hours at 25 0c under constant vibration. After 
a 48-hour period the saturated solution was filtered through 
a 0.45 μm Millipore filter and analyzed.  
BULK PROPERTIES
Rania et al. (2008) suggested pre compression stu-
dies of the Liquisolid powder systems. In the  study, he 
suggested flowability of a powder is of major importance 
in the production of pharmaceutical dosage forms in order 
to attain a uniform feed and reproducible filling of tablet 
dies. The following parameters describe a measure of the 
flow properties of liquisolid systems that will be selected 
and compressed into tablets.
Angle of Repose Method: In this method, a fixed 
height cone method procedure was performed in triplicate 
and average angle of repose calculated (Rania et al.,2008).
 (h)
Angle of repose   Tan θ =  ––
 
r
Bulk Density: This procedure involves the fixed 
height of each liquisolid powder substrate with prepared 
and fixed weight. This powder was placed in a graduated 
cylinder and the powder occupation volume measured 
and initial bulk density D B min  calculated. The graduated 
cylinder was then allow to tap at constant velocity until a 
constant volume is obtained, when the powder was con-
sidered to have reached the most stable arrangement, the 
final bulk volume was recorded. Final bulk density D B max 
was then calculated. (Rania et al.,2008). 
 DB max – DB min  
             
Carr’s index % =  ––––––––––– × 100
 DB max 
“Hausner” s ratio was calculated from the equation
 DB max“Hausner’s” ratio = –––––
 
DB min
Angle of Slide: For the determination of angle of 
slide, an approximately weighed amount of coating mate-
rial was placed at one end of a metal plate with a polished 
surface. This end was raised gradually until the plate for-
med an angle with the horizontal at which the powder was 
about to slide. This angle θ represents the angle of slide. 
It was taken as a measure for the flow characteristics of 
powders. An angle of slide of 330 corresponds to optimal 
flow properties (Spireas et al., 1999).
Contact Angle:  For assessment of wettability, con-
tact angle of Liquisolid tablets was measured according to 
the imaging method. To measure the contact angle, a drop 
of liquid is directly placed on a flat surface of the solid in 
the–so-called imaging method. The liquid drop is prepared 
using a saturation solution of the drug in Simulated Gastric 
Fluid, Simulated Intestinal Fluid media and an excessively 
large amount of pure drug was added to this media, shaken 
for 24 hours at a constant rate then the upper solution 
was centrifuged. A drop of this solution was placed on 
the surface of the tablet, and pictures were taken using 
a digital camera. By measuring the height and diameter 
of the sphere drop on the (Spireas et al., 1999) liquisolid 
tablets and direct compressed tablets, contact angle was 
measured. Liquisolid tablet contact angle is less than that 
of direct compressed tablets. Polysorbate 80 showed the 
lowest contact angle in the liquisolid tablets.
Dissolution studies on Liquisolid tablets
This entails the optimization of the hardness of the 
Liquisolid tablet, without applying excessive compression 
force yet assuring rapid disintegration and dissolution. In 
other words, tablets should be sufficiently hard to resist 
breaking during normal handling and yet quickly disinte-
grate properly after swallowing. 
Dissolution rate (DR) is explained according to the 
“Noyes – Whitney” equation and “diffusion layer model” 
dissolution theories.
DR = (D/h) S (Cs- C)
According to this equation, stagnant diffusion layer 
thickness is h, and formed by the dissolving liquid around 
the drug particles. D is the diffusion coefficient of the 
drug molecules transported through it, S is the surface 
area of the drug available for dissolution, C is the drug 
concentration in the bulk of the dissolving medium, Cs 
is the saturation solution of the drug in the dissolution 
medium. Dissolution tests for liquisolid tablets were done 
at constant rotational speed and in identical dissolution 
media, thus allowing estimation of the thickness of the 
stagnant diffusion layer (h). From this equation, disso-
lution rate is directly proportional not only to the con-
centration gradient of the drug in the stagnant diffusion 
layer (Cs- C), but also to its surface area (S) available 
for dissolution.
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For estimation and comparison, drug dissolution 
rates (DR) of drug were used, with amount of drug dissol-
ved per min presented by each tablet formulation during 
the first 10 minutes.  
 
(M x D)DR = –––––––
 
1000
Where, M is the total amount of pure drug in each 
tablet and D is the percentage of drug dissolved in the first 
10 minutes (Spireas et al., 1998)
Importance of carrier and coating material 
ratio(R): Liquisolid systems pre compression and drug 
release properties increase with powder excipient ratios ( 
R ) from 5:1 to 50:1. A linear relationship exists between 
the liquid load factors Lf and the reciprocal powder exci-
pient ratios (1/R) required to produce acceptable flowing 
and readily compressible liquid / powder admixtures. The 
linear relationship between Lf and the 1/ R plot of liquisolid 
systems possesses Y intercept and slope equal to the Φ 
values of the cellulose carrier powder and silica coating 
material (Javadzadeh et al., 2007)
Liquisolid system dissolution rate profiles are 
affected by powder excipients ratio R in which results 
exhibited within the 5 minutes of the dissolution process 
against the r values 5 to 20 range R values. The dissolution 
rates increased almost proportionally to R until reaching 
an apparent maximum plateau at powder excipient ratios 
greater than 20.
Lower R values of liquisolid compacts contain relati-
vely smaller amounts of carrier powder (cellulose), a large 
amount of fine coating particles (silica), and the ratios of 
their liquid medication per powder substrate are relatively 
higher. From the low liquid / powder ratios, a high presence 
of cellulose and low presence of silica may be directly as-
sociated with enhanced wicking, disintegration, and degra-
dation properties. Low R values should justifiably display 
relatively poor dissolution profiles. After disintegration, 
low R values of liquisolid tablets are overloaded with liquid 
medication  producing the primary particles.
On other hand, in some cases, the drug diffusion 
through the primary particles may be rapid and might lead to 
overwhelming (solubility- wise) of the stagnant dissolution 
layers with drug. After maximum levels of dissolution are 
reached at 35 to 45 R values, a slight gradual decrease of 
dissolution rate occurs with increasing powder excipient 
ratios. For R values higher than 50, they may be attributed 
to the slower diffusion of the liquid medication through the 
numerous porous carrier powder particles into which the 
drug solution has been embedded during the formulation 
process. To determine the effect of different type of car-
riers such as Avicel, lactose, starch or sorbitol, dissolve in 
solution containing 10% w/w of drug in liquid medication. 
Carriers show the potential to absorb the liquid medication. 
Large amounts of these carriers are necessary for regene-
rating liquid medication to dry looking and non adherent 
powder. Avicel ® PH 102 showed better results, due to its 
large specific area in comparison with other carriers such 
as lactose and starch (Javadzadeh et al., 2007). 
Type of carrier might affect the unit size of liquisolid 
tablets. Higher Avicel® PH 102 concentrations show uni-
form distribution of the drug by either adsorption onto or 
absorption into the carrier. Between the hydrogen groups, 
hydrogen bonds on adjacent cellulose molecules in Avicel® 
PH 102 may account exclusively for the strength and cohe-
siveness of compacts. Avicel® PH 102 compressibility and 
compactness characteristics can be explained by the nature 
if crystalline cellulosic particles themselves which are held 
together by hydrogen bonds which when compressed, are 
deformed plastically and a strong compact is formed due to 
the extremely excessive number of surfaces brought into 
contact during the plastic deformation, and the strength 
of the hydrogen bonds are formed (Fahmy et al.,2008). 
Surface active agent Polysorbate 80 was shown to 
facilitate wetting of drug particles by decreasing interfa-
cial tension between dissolution medium and the tablet 
surface. Increase in the wetting properties of liquisolid 
tablets by the dissolution media is one of the main reasons 
for the dissolution rate enhancement. High R values 30 to 
60 evidence better uniform distribution of the drug in the 
carrier material (Tayel et al., 2007).
PRE COMPRESSION STUDIES
Polymorphic changes of the drug are important fac-
tors that may affect the dissolution rate and bio availability. 
Prior to the compression of the formulation into tablets, 
and in order to ensure the suitability and selection of 
excipients, various studies were performed including Di-
fferential Scanning Calorimetry (DSC), X-Ray Powdered 
Diffraction (XRPD), and Scanning Electron Microscopic 
studies.  In order to assess the thermo tropic properties and 
the thermal behaviors of the drug, carriers such as Avicel® 
PH 102, coating material such as Aerosil® PH 200 as well 
as liquisolid  tablets were used.  
Yousef Javadzadeh et al. (2008) suggested that the 
liquisolid technique has the potential to be optimized for 
the reduction of drug dissolution rate and thereby produc-
tion of sustained release systems. The results also showed 
that wet granulation had a marked impact on reducing 
dissolution release rate of propranolol HCl from liquisolid 
formulations (Javadzadeh et al., 2008).
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Rania et al. (2008) reported that famotidine liquiso-
lid tablets reached a maximum result within 30 minutes 
and compared to conventional tablets showed higher a 
dissolution pattern in both rate and extent of drug. Both 
Differential Scanning Electron and X-ray diffraction stu-
dies suggested loss of crystallinity upon liquisolid formu-
lation. This was further confirmed by Scanning Electron 
Microscopic studies indicating that even though the drug 
existed in a solid dosage form, it is held within the powder 
substrate in a solubilized, almost molecularly dispersed 
state, which contributed to the enhanced drug dissolution 
properties. In addition, the selected optimal formula rele-
ased 78.36% of its content during the first 10 min which 
is 39% higher than that of the directly compressed tablets. 
Further, the bioavailability study indicated that the prepa-
red optimal liquisolid formula did not differ significantly 
from the marketed famotidine tablets concerning Cmax, tmax, 
and AUC(0–8) at P < 0.05 .
Tayel et al. (2008) reported that Carbamazepine 
liquisolid tablets showed better dissolution rates, rapid 
disintegration and good wettability comparable to the 
generic product by using Avicel®PH 200 at a 20:1 carrier 
and coating material ratio.
In a study by Yousef Javadzadeh et al. (2007), in 
order to reduce the amounts of carrier and Aerosil PH 200 
in liquisolid formulations, some additives namely, Poly 
Vinyl Pyrrolidone (PVP), Hydroxy Propyl Methylcellulo-
se (HPMC) and Poly Ethylene glycol (PEG 35000) were 
added to liquid medication to increase loading factor. The 
results showed that the drug loading factor was increased 
significantly in the presence of additives. It was shown 
that microcrystalline cellulose had more liquid retention 
potential in comparison with lactose, and the formula-
tions containing microcrystalline cellulose as a carrier 
showed a higher dissolution rate. By decreasing the ratio 
of microcrystalline cellulose to silica from 20 to 10, an 
improvement in dissolution rate was observed. Further 
decrease in the ratio of microcrystalline cellulose: silica 
from 10 to 5 resulted in a significant reduction in dissolu-
tion rate. Increasing PVP concentration in liquid medica-
tion caused a dramatic increase in dissolution rate during 
the first 30 min. The results showed that the dissolution 
rate of liquisolid tablets was not significantly affected by 
storing the tablets at 25 °C/75% relative humidity for a 
period of 6 months.
Yousef Javadzadeh et al. (2007) investigated the effect 
of type of carrier on dissolution rate of piroxicam from liqui-
solid tablets involving lactose, starch, sorbitol, Avicel. This 
study suggested that Avicel had more liquid retention poten-
tial due to the high specification area of Avicel (1.18 m2/g) 
in comparison with other carriers lactose (0.35 m2/g), starch 
(0.6 m2/g) and sorbitol (0.37 m2/g), but a larger amount of 
these carriers is necessary for converting liquid medication 
to dry-looking , non-adherent  powder.
Javadzadeh et al. (2005) reported that surface active 
agent polysorbate 80 facilitated wetting of drug particles 
by decreasing interfacial tension between dissolution 
medium and tablet surface. Increase in the wetting pro-
perties of liquisolid tablets by the dissolution media is 
one of the main reasons for the piroxicam dissolution rate 
enhancement.
Ali et al. (2005) found that, from the indomethacin 
liquisolid tablets, the amount of drug release at pH 7.2 
is greater than that released at pH 1.2 due to the higher 
solubility of indomethacin at higher pH values.
Khaled et al. (2001) reported that hydrochlorothia-
zide liquisolid tablets showed significantly greater extent 
of absorption than commercial tablets. Therefore, this for-
mulation of the drug has the potential to be considered for 
human study in order to be manufactured on a large scale.
 Studies by Spireas et al.(1999)  reported it is quite 
possible that liquisolid compacts might exhibit more con-
sistent and enhanced absorption characteristics compared 
to commercial methyclothiazide tablets .
Spireas et al. (1998) concluded that the dissolu-
tion rate of prednisolone from the liquisolid compacts is 
independent of the dissolution volume, whereas direct 
compressed tablets of the micronized drug display de-
clining dissolution rates with decreasing volumes of the 
dissolving medium.
In a study on hydrocortisone liquisolid tablets, Spire-
as et al. (1998) reported that, due to their increased wetting 
properties and surface of drug available for dissolution, 
these tablets demonstrated significantly higher drug relea-
se rates than those conventionally made, direct compressed 
marketed products. Also, these authors observed that the 
drug release superiority of liquisolid tablets is inversely 
proportional to the aqueous solubility of the contained 
drug. Liquisolid tablets demonstrated significantly faster 
drug dissolution patterns in small volumes of dissolution 
media such as 450 mL and 300 mL 
Studies by Javadzadeh Y., et al. (2009)  provide 
evidence that among the different grades of MCC evalua-
ted, compacts containing MCC® PH 101 and 102 showed 
better hardness, friability and  dissolution profile. Aging 
had no effect on hardness or dissolution profile of liqui-
solid tablets prepared from MCC PH 101. Finally, this 
study reported that MCC PH 101 is a suitable carrier for 
preparing liquisolid systems in terms of having acceptable 
flowability, friability, hardness, and dissolution profile.
Tiong N et al. (2009) reported that naproxen pro-
perties were changed by adding non-volatile hydrophilic 
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solvent, leading to an increase in dissolution properties 
and possibly oral bio-availability.
CONCLUSION
In conclusion, Liquisolid technology was effective 
for improving dissolution rate as well as bio-availability 
in practically water insoluble drugs with non-volatile 
solvents. The technique also sustained the drug release 
properties of the water soluble drugs by using suitable 
biodegradable polymers with appropriate excipient ratios.
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